Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Overview
Björn Mellgård, M.D., Ph.D., Vice President, Global Program Lead, Rare Genetics and Hematology, Takeda, breaks down Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Björn Mellgård, M.D., Ph.D., Vice President, Global Program Lead, Rare Genetics and Hematology, Takeda, breaks down Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
The National Organization of Rare Diseases (NORD) has launched a FREE Rare Disease Education course for students. Health
HomePages Pittsburgh, Pennsylvania | June 28-29, 2024 2024 FOD/OAA Family Forum Registration on Eventbrite – Click Here Wyndham Hotel Reservations – Click Here Scholarship Request…
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Approval allows Onivyde (plus oxaliplatin, fluorouracil, and leucovorin) as first-line therapy.
The first-in-class oral factor B inhibitor iptacopan improves hematologic and clinical outcomes in anti-C5-treated patients with persistent anemia and in those who have not received…
Find facts and the latest research around 3q29 deletion syndrome and 3q29 duplication syndrome. Learn about these rare genetic conditions, how you can participate in…
For older patients with acute myeloid leukemia undergoing allo-HCT, posttransplant outcomes have improved over time.
InnoVision Marketing Group, a San Diego-based agency, is selected as agency of record for the ALS Association.
From having to quit the army, to fear of burdening his family, Tre Archibald’s life changed after diagnosis.